Our results showed that ABCC5, ABCC4 and ABCD3 were significantly under expressed in CP-CML patients after 12 months of nilotinib treatment compared to diagnosis [18]. This evidence concerns the gene ABCD3 and chronic myelogenous leukemia, BCR-ABL1 positive.